Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Down 7.2% – Here’s What Happened

Posted by Jeff Wilder on Sep 16th, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s share price dropped 7.2% on Monday . The stock traded as low as $44.1979 and last traded at $44.1979. Approximately 275 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 2,766 shares. The stock had previously closed at $47.64.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Barclays lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Finally, Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Check Out Our Latest Stock Report on Zealand Pharma A/S

Zealand Pharma A/S Stock Performance

The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of 7.13 and a beta of 0.89. The company has a 50 day simple moving average of $47.40 and a 200-day simple moving average of $46.90. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.